Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
32.4 SEK | 0.00% | +1.25% | +28.57% |
04-18 | Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-22 | Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.57% | 32.34M | - | ||
+31.07% | 588B | B | ||
-3.42% | 364B | C+ | ||
+18.02% | 326B | B- | ||
+4.27% | 285B | C+ | ||
+14.79% | 239B | B+ | ||
+10.18% | 210B | B- | ||
-6.95% | 200B | A+ | ||
+8.12% | 167B | C+ | ||
-1.42% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- MAGLE Stock
- Ratings Magle Chemoswed Holding AB